There is a version of medical device development that treats clinical research as a late-stage obligation, a regulatory hurdle to clear before a product reaches market. Dr David Hayes has spent his career arguing against that version. As Chief Medical Officer at BIOTRONIK, he has watched what happens when clinical evidence is built into the foundation of device development, and what happens when it isn't. In a recent Clinical Compass podcast episode, Dr Hayes joined Trisha Pillay to discuss how pharma and medtech leaders should approach clinical research, collaboration, and the evolving evidence standards shaping the future of cardiac device innovation.Clinical Research Is Not a CheckboxClinical research in the context of medical devices is not the same as confirming a product works under controlled conditions. It is the systematic evaluation of how a device performs in real physiological and clinical environments, across diverse patient populations, under the conditions of actual care delivery."Clinical research evaluates devices in real environments," Hayes emphasises. The distinction matters enormously. A device that performs well in a controlled trial may behave differently when implanted in an elderly patient with comorbidities, or in a centre where workflows differ from the study protocol. Regulatory bodies, including the FDA, are increasingly demanding evidence that reflects this complexity, not just pre-market efficacy data, but ongoing demonstration of real-world performance.For pharma and medtech leaders, this reframes the question from "what do we need to get approved?" to "what do we need to know to be confident this device is safe and effective for the patients who will actually receive it?" Those are not always the same question, and the gap between them is where post-market surprises happen.The Collaboration ImperativeHayes is direct about what separates device programmes that generate meaningful clinical evidence from those that don't: the quality of collaboration between manufacturers and the clinical community."Feedback drives design updates and regulatory approval," he notes, and the feedback loop he is describing needs to start far earlier than most organisations do. By the time a device reaches late-stage trials, fundamental design decisions have already been made. Engaging clinicians at that point means incorporating their insights into documentation and labelling, not into the product itself. The more valuable model, in Hayes' experience, involves key opinion leaders and front-line clinicians in active dialogue during development. He recounts a recent focus group where KOL input led to substantive design changes in a product still in development. That kind of iteration is only possible when clinical intelligence is treated as a design input, not a post-hoc validation exercise. For leaders building clinical development strategies, the implication is structural; clinical affairs teams need a seat at the product development table from the outset, with mechanisms to surface and act on clinician feedback throughout the programme lifecycle.The Patient DimensionThroughout the conversation, Hayes returns to a point that can get lost in the regulatory and commercial calculus, and that is the patient is the end-user, and their experience of the device matters. Structured patient advisory input remains underdeveloped across the industry. Gathering patient perspectives informally, or only after a product is already designed, forecloses the most impactful opportunities to improve usability, adherence, and outcomes. Hayes sees formalising patient input as one of the areas with the greatest room for improvement and, increasingly, as a dimension that regulators and payers are beginning to weigh more heavily in their assessments. For pharma and device leaders, the strategic reading of Hayes' perspective is consistent, and that is the organisations that treat clinical research as a core competency rather than a compliance function will build better products, face fewer regulatory surprises, and ultimately serve patients more effectively. For more information, visit BIOTRONIK or connect with Dr David Hayes on LinkedIn.TakeawaysImportance of clinical research in medical device development.Collaboration between industry and healthcare providers.Regulatory compliance and post-market surveillance.Use of real-world evidence to improve device safety and efficacy.Patient-centred design approaches.Chapters00:00 - Introduction to Clinical Research and Innovation01:00 - The Role of Clinical Trials in Cardiac Device Development04:12 - Importance of Collaboration in Clinical Research10:11 - Incorporating Patient Feedback into Product Design12:10 - Navigating Regulatory Challenges in Medical Device Innovation15:36 - Real-World Evidence and Its Impact on Device Functionality18:54 - Strategies for Smaller Companies in Clinical Research22:24 - The Future of Clinical Research and Patient Outcomes
Show More
Show Less
24 mins